ZA200006340B - Dhea composition and method. - Google Patents

Dhea composition and method.

Info

Publication number
ZA200006340B
ZA200006340B ZA200006340A ZA200006340A ZA200006340B ZA 200006340 B ZA200006340 B ZA 200006340B ZA 200006340 A ZA200006340 A ZA 200006340A ZA 200006340 A ZA200006340 A ZA 200006340A ZA 200006340 B ZA200006340 B ZA 200006340B
Authority
ZA
South Africa
Prior art keywords
dhea
composition
dhea composition
Prior art date
Application number
ZA200006340A
Other languages
English (en)
Inventor
Jagdish Parasrampuria
Maxine B Yonker
Kenneth E Schwartz
Marc J Gurwith
Original Assignee
Genelabs Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Tech Inc filed Critical Genelabs Tech Inc
Publication of ZA200006340B publication Critical patent/ZA200006340B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
ZA200006340A 1999-03-18 2000-11-06 Dhea composition and method. ZA200006340B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12520199P 1999-03-18 1999-03-18

Publications (1)

Publication Number Publication Date
ZA200006340B true ZA200006340B (en) 2001-05-23

Family

ID=22418636

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200006340A ZA200006340B (en) 1999-03-18 2000-11-06 Dhea composition and method.

Country Status (14)

Country Link
EP (2) EP1778246A2 (xx)
JP (1) JP2002539158A (xx)
KR (1) KR20010043716A (xx)
CN (2) CN100544726C (xx)
AU (1) AU779138B2 (xx)
BR (1) BR0005392A (xx)
CA (1) CA2332767A1 (xx)
IL (1) IL139386A (xx)
MX (1) MXPA00011329A (xx)
NO (1) NO327981B1 (xx)
NZ (1) NZ507880A (xx)
RU (1) RU2220727C2 (xx)
WO (1) WO2000054763A2 (xx)
ZA (1) ZA200006340B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605591B1 (en) 1999-11-12 2003-08-12 Genelabs Technologies, Inc. Treatment of subnormal bone mineral density
US6552010B1 (en) 1999-11-12 2003-04-22 Genelabs Technologies, Inc. Treatment of SLE with dehydroepiandrosterone
WO2002085297A2 (en) 2001-04-24 2002-10-31 East Carolina University Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
US7405207B2 (en) 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
EP1553954A4 (en) * 2002-06-17 2009-12-23 Epigenesis Pharmaceuticals Llc DIHYDRATE DEHYDROEPIANDROSTERONE AND METHOD FOR THE TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE LUNG DISEASE, COMPOSITIONS THEREOF
EP2734193B1 (en) 2011-07-19 2015-05-20 Pantarhei Bioscience B.V. Tablet containing dehydroepiandrosterone (dhea)
EP2986634B1 (en) * 2013-04-19 2019-11-20 University of Houston System Cocrystalline dhea formulations
RU2545812C1 (ru) * 2014-02-24 2015-04-10 Аллан Герович Бениашвили Ородисперсная таблетка дегидроэпиандростерона
RU2557960C1 (ru) * 2014-07-01 2015-07-27 Аллан Герович Бениашвили Ородисперсная таблетка дегидроэпиандростерона и/или комбинации дегидроэпиандростерона и l-тианина
CN113406254B (zh) * 2021-07-21 2023-03-07 裕菁科技(上海)有限公司 一种同时检测多种外源性和内源性甾体激素的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518595A (en) 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
US5077284A (en) 1988-12-30 1991-12-31 Loria Roger M Use of dehydroepiandrosterone to improve immune response
IE63051B1 (en) * 1989-03-18 1995-03-22 Akzo Nv Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one
ZA924811B (en) 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
WO1994008589A1 (en) 1992-10-09 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Treatment of systemic lupus erythematosus with dehydroepiandrosterone
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
JP3862295B2 (ja) 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
US5855548A (en) 1996-06-14 1999-01-05 Vivus, Incorporated Venous flow control element for maintaining penile erection
US5861391A (en) 1997-01-29 1999-01-19 Research Development Foundation Use of dehydroepiandrosterone to treat primary adrenal insufficiency and Addison's disease
US5935949A (en) 1998-03-20 1999-08-10 Trustees Of Dartmouth College Use of androgen therapy in fibromyalgia and chronic fatigue syndrome

Also Published As

Publication number Publication date
AU779138B2 (en) 2005-01-06
IL139386A0 (en) 2001-11-25
NO20005763L (no) 2001-01-10
CN101543500A (zh) 2009-09-30
KR20010043716A (ko) 2001-05-25
NO20005763D0 (no) 2000-11-14
WO2000054763A2 (en) 2000-09-21
CN1407897A (zh) 2003-04-02
NO327981B1 (no) 2009-11-02
MXPA00011329A (es) 2002-04-17
BR0005392A (pt) 2001-01-30
NZ507880A (en) 2003-12-19
JP2002539158A (ja) 2002-11-19
CA2332767A1 (en) 2000-09-21
EP2233141A1 (en) 2010-09-29
IL139386A (en) 2006-08-01
WO2000054763A3 (en) 2001-09-07
RU2220727C2 (ru) 2004-01-10
CN100544726C (zh) 2009-09-30
EP1778246A2 (en) 2007-05-02
AU3753900A (en) 2000-10-04

Similar Documents

Publication Publication Date Title
EP1176948A4 (en) COMPOSITIONS AND METHODS
ZA200203367B (en) Antidiabetic formulation and method.
GB2348808B (en) Methods and compositions for desensitisation
HUP0201188A2 (en) Hemisynthetic method and new compounds
ZA200108217B (en) Application apparatus and method.
GB0023659D0 (en) Dispersion composition and method for producing the same
EP1223932A4 (en) COMPOUNDS AND METHODS
EP1146790A4 (en) COMPOUNDS AND METHODS
AU6832101A (en) Composition and method
IL148803A0 (en) Novel composition and method for stabilizing the same
AU4163402A (en) Composition and method
ZA200201816B (en) A vaccine composition and method of using the same.
EP1056456A4 (en) R-LANSOPRAZOL COMPOSITIONS AND TREATMENTS THEREFOR
EP1056457A4 (en) S-LANSOPRAZOLE COMPOSITIONS AND METHODS OF USE
MXPA02003232A (es) Composiciones y metodos para alternar la expresion de genes.
ZA200006340B (en) Dhea composition and method.
EP1073333A4 (en) S-RABEPRAZOL COMPOSITIONS AND METHODS
GB9803506D0 (en) Composition and method
AU2001233932A1 (en) Method and composition
IL145220A0 (en) Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process
GB9922135D0 (en) Compositions and uses
AU2002239775A1 (en) Chemical-library composition and method
GB0318112D0 (en) ›-Secretase enzyme compositions and methods
EP1073332A4 (en) R-RABEPRAZOL COMPOSITIONS AND METHODS
EP1272512A4 (en) IMMUNOKIN COMPOSITION AND METHOD